Nitrogen Attached Directly Or Indirectly To The Hetero Ring By Acyclic Nonionic Bonding Patents (Class 549/419)
  • Patent number: 9834534
    Abstract: Compounds having a structure of Formula I and compositions comprising these compounds are provided. Uses of such compounds and compositions are provided for treatment or prophylaxis of viral infection. In particular, compounds and compositions may be for use in the treatment or prophylaxis of viral influenza.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: December 5, 2017
    Assignee: The University of British Columbia
    Inventors: Stephen Withers, Andrew Graham Watts, Jin Hyo Kim, Tom Wennekes
  • Patent number: 9458124
    Abstract: Certain 3,6-disubstituted and 2,4,5-trisubstituted pyran derivatives that exhibit potent activity on monoamine transport systems are provided. The 3,6 and 2,4,5 pyrans are useful in probing the effects of their binding to monoamine transporter systems and the corresponding relationships to various afflictions affecting the CNS, or as a treatment for various CNS-related disorders in which the monoamine transport and related systems are implicated.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: October 4, 2016
    Assignee: Wayne State University
    Inventor: Aloke K. Dutta
  • Patent number: 9382284
    Abstract: Compounds having a structure of Formula I and compositions comprising these compounds are provided. Uses of such compounds and compositions are provided for treatment or prophylaxis of viral infection. In particular, compounds and compositions may be for use in the treatment or prophylaxis of viral influenza.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: July 5, 2016
    Assignee: The University of British Columbia
    Inventors: Stephen Withers, Andrew Graham Watts, Jin Hyo Kim, Tom Wennekes
  • Patent number: 9102647
    Abstract: Disclosed is a method for preparing lactide by using a solvent. According to the method, since an ionic liquid is used as a solvent in a second step in the course of preparing lactide, it is possible to secure mobility of the resulting reactant, and decrease a reaction temperature. In addition, the ionic liquid absorbs moisture generated during the reaction, and thus prevents degradation of lactide which is susceptible to moisture. Furthermore, to the present method allows for the preparation of lactide successively through the continuous supply of lactic acid oligomers. Because the use of an ionic liquid minimizes the contamination of a reactive group with by-products, the use of a solvent for reactor washing is unnecessary. Further, owing to a high boiling point of the ionic liquid, the ionic liquid can be easily harvested and recycled.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: August 11, 2015
    Assignee: Hyundai Motor Company
    Inventors: Si Hwan Kim, Chae Hwan Hong, Do Suck Han, Ji Yeon Seo
  • Publication number: 20150148347
    Abstract: A compound of formula I, wherein the groups R1, R2, R3, X, m, and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
    Type: Application
    Filed: November 25, 2014
    Publication date: May 28, 2015
    Inventors: Iain LINGARD, Dieter HAMPRECHT
  • Patent number: 8952183
    Abstract: The present invention describes compounds of Formula I or a pharmaceutically acceptable salts or derivatives thereof. Compositions comprising compounds of Formula I are also described. The present invention further relates to a method of producing non-2-enonate compounds.
    Type: Grant
    Filed: May 4, 2010
    Date of Patent: February 10, 2015
    Assignee: National Research Council of Canada
    Inventors: Ian C. Schoenhofen, Dennis M. Whitfield, Susan M. Logan
  • Patent number: 8937189
    Abstract: Novel 3,6-disubstituted pyrans, optionally with a further substituent at the 4-position, are monoamine reuptake inhibitors with activity profiles of antidepressants.
    Type: Grant
    Filed: August 26, 2013
    Date of Patent: January 20, 2015
    Assignee: Wayne State University
    Inventor: Aloke K. Dutta
  • Patent number: 8907111
    Abstract: Compounds having a structure of Formula I and compositions comprising these compounds are provided. Uses of such compounds and compositions are provided for treatment or prophylaxis of viral infection. In particular, compounds and compositions may be for use in the treatment or prophylaxis of viral influenza.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: December 9, 2014
    Assignee: The University of British Columbia
    Inventors: Stephen Withers, Andrew Graham Watts, Jin Hyo Kim, Tom Wennekes
  • Publication number: 20140336396
    Abstract: The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.
    Type: Application
    Filed: May 16, 2014
    Publication date: November 13, 2014
    Applicants: Cardioxyl Pharmaceuticals, Inc., The Johns Hopkins University
    Inventors: John P. Toscano, Frederick Arthur Brookfield, Andrew D. Cohen, Stephen Martin Courtney, Lisa Marie Frost, Vincent Jacob Kalish
  • Publication number: 20140336137
    Abstract: The invention relates to nitroso derivatives including carboxylic acid and phosphoric acid esters of hydroxy nitroso compounds that donate nitroxyl (HNO) under physiological conditions. The compounds and compositions of the invention are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure, ischemia/reperfusion injury and cancer.
    Type: Application
    Filed: July 28, 2014
    Publication date: November 13, 2014
    Inventors: Lisa Marie Frost, Stephen Martin Courtney, Frederick Arthur Brookfield, Vincent Jacob Kalish
  • Patent number: 8877754
    Abstract: The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: November 4, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Gerald Juergen Roth, Martin Fleck, Heike Neubauer, Bernd Nosse
  • Publication number: 20140309427
    Abstract: Certain 3,6-disubstituted and 2, 4, 5-trisubstituted pyran derivatives that exhibit potent activity on monoamine transport systems are provided. The 3, 6 and 2, 4, 5 pyrans are useful in probing the effects of their binding to monoamine transporter systems and the corresponding relationships to various afflictions affecting the CNS, or as a treatment for various CNS-related disorders in which the monoamine transport and related systems are implicated.
    Type: Application
    Filed: February 6, 2014
    Publication date: October 16, 2014
    Inventor: Aloke K. DUTTA
  • Publication number: 20140249105
    Abstract: Compounds, ceramide analogues, having a cyclic structure derived from cyclopropane, cyclobutane or cyclopentane, the ring bearing two chains consisting of an amide function. Each amide function is attached to the ring by the nitrogen atom of the function and carries a hydrocarbon chain derived from a fatty acid. The amide functions can be cis or trans relative to one another. Processes for the preparation of these novel compounds as well as pharmaceutical and/or cosmetic compositions containing them.
    Type: Application
    Filed: July 25, 2011
    Publication date: September 4, 2014
    Applicant: Diverchim
    Inventors: Jean-Louis Brayer, Natacha Frison, Benoit Folleas
  • Patent number: 8822658
    Abstract: 4?-epidaunorubicin hydrochloride is provided in a crystalline form which is stable and readily soluble. A process of producing the crystalline form includes crystallizing 4?-epidaunorubicin hydrochloride in a solvent system including (a) solvent A selected from C1 and C2 halogenated solvents and mixtures thereof, (b) solvent B selected from C1-C5 straight and branched alcohols and mixtures thereof, and (c) solvent C selected from C1-C5 straight and branched alcohols and mixtures thereof, wherein solvent C is selected to provide lower solubility to 4?-epidaunorubicin hydrochloride than solvent B. A method of producing an anthracycline using crystalline 4?-epidaunorubicin hydrochloride is also provided.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: September 2, 2014
    Assignee: Heraeus Precious Metals GmbH & Co. KG
    Inventors: Tero Kunnari, Holger Bindernagel, Sascha Weiser, Andrew Lupton, Stefan Wallert
  • Publication number: 20140235636
    Abstract: The invention provides certain N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invention provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or develop of a disease or condition. In some embodiments, the disease or condition is selected from cardiovascular diseases, ischemia, reperfusion injury, cancerous disease, pulmonary hypertension and conditions responsive to nitroxyl therapy.
    Type: Application
    Filed: April 25, 2014
    Publication date: August 21, 2014
    Applicants: Cardioxyl Pharmaceuticals, Inc., The Johns Hopkins University
    Inventors: John P. Toscano, Art Sutton, Vincent Jacob Kalish, Frederick Arthur Brookfield, Stephen Martin Courtney, Lisa Marie Frost
  • Publication number: 20140221657
    Abstract: Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a compound relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed.
    Type: Application
    Filed: April 7, 2014
    Publication date: August 7, 2014
    Applicant: PRISM BioLab Corporation
    Inventors: Hiroyuki Kouji, Yuji Kogami, Takenao Odagami
  • Patent number: 8735590
    Abstract: The present invention provides bicyclo-heptan-2-amines that selectively bind to the sigma-2 receptor and are useful in the treatment of diseases related to the sigma-2 receptor, for example, cancer and neurological disorders.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: May 27, 2014
    Inventors: Adeboye Adejare, Zeynep Ates-Alagoz, Boyenoh Gaye
  • Patent number: 8686164
    Abstract: 4?-epidaunorubicin hydrochloride is provided in a crystalline form which is stable and readily soluble. A process of producing the crystalline form includes crystallizing 4?-epidaunorubicin hydrochloride in a solvent system including (a) solvent A selected from C1 and C2 halogenated solvents and mixtures thereof, (b) solvent B selected from C1-C5 straight and branched alcohols and mixtures thereof, and (c) solvent C selected from C1-C5 straight and branched alcohols and mixtures thereof, wherein solvent C is selected to provide lower solubility to 4?-epidaunorubicin hydrochloride than solvent B.
    Type: Grant
    Filed: September 8, 2010
    Date of Patent: April 1, 2014
    Assignee: Heraeus Precious Metals GmbH & Co. KG
    Inventors: Tero Kunnari, Holger Bindernagel, Sascha Weiser, Andrew Lupton, Stefan Wallert
  • Publication number: 20140058120
    Abstract: Novel 3,6-disubstituted pyrans, optionally with a further substituent at the 4-position, are monoamine reuptake inhibitors with activity profiles of anti-depressants.
    Type: Application
    Filed: August 26, 2013
    Publication date: February 27, 2014
    Applicant: Wayne State University
    Inventor: Aloke K. Dutta
  • Patent number: 8658693
    Abstract: The present invention provides novel selective androgen receptor modulators and their salts and pharmaceutical compositions thereof.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: February 25, 2014
    Assignee: Eli Lilly and Company
    Inventors: Jonathan Edward Green, Prabhakar Kondaji Jadhav, Venkatesh Krishnan, Donald Paul Matthews, Ashraf Saeed, Gregory Alan Stephenson
  • Patent number: 8614335
    Abstract: There is provided a process for the preparation of a compound of formula (7) or salts thereof: wherein R1 represents a hydrogen or a hydrocarbyl group, R2 represents a hydrogen or substituent group, R3 represents a hydrogen or a hydrocarbyl group, and X represents a hydrogen or substituent group which comprises a) cyanating a compound of formula (1): wherein Y represents a halo group, preferably CI or Br; P1 represents hydrogen or a protecting group, and W represents ?O or —OP2, in which P2 represents hydrogen or a protecting group, to give a compound of formula (2): b) reducing the compound of formula (2) to give a compound of formula (3): coupling the compound of formula (3) with a compound of formula (4): to give a compound of formula (5): when W represents —OP2, deprotecting and then oxidizing the compound of formula (5) to give a compound of formula (6): and e) subjecting the compound of formula (5) when W represents ?O, or compound of formula (6) to ring-opening, and removal of any remaining protecting
    Type: Grant
    Filed: August 14, 2008
    Date of Patent: December 24, 2013
    Assignee: Redx Pharma Limited
    Inventors: David John Moody, Jonathan William Wiffen
  • Publication number: 20130316286
    Abstract: Provided is a photoresist composition containing a polymer that contains, as a constituent unit, a specific methacrylic acid ester derivative. The photoresist composition can form a photoresist pattern with improved LWR and high resolution. More specifically, provided is an acrylic acid ester derivative represented by the following general formula (1): wherein R1 is a hydrogen atom or a methyl group; and A represents the following general formula (A-1) or (A-2): wherein R2 and R3 are each independently an alkyl group having 1 to 6 carbon atoms or a cyclic hydrocarbon group having 3 to 6 carbon atoms; Z is CH2 or —O—; and n is 0 or 1; with the proviso that in (A-1) there is no case where R2 is a methyl group and Z is CH2 and n is 1.
    Type: Application
    Filed: January 18, 2012
    Publication date: November 28, 2013
    Applicant: KURARAY CO., LTD.
    Inventor: Osamu Nakayama
  • Publication number: 20130303568
    Abstract: The invention is directed to substituted 2-aminoacetamides represented by formula (II): and to pharmaceutically acceptable salts and prodrugs thereof, wherein the substituents are defined herein. The invention is also directed to the use of substituted 2-aminoacetamides in methods for the treatment of neuronal damage following global and focal ischemia, and for the treatment, prevention or amelioration of pain, anxiety, or manic depression, as anticonvulsants, as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.
    Type: Application
    Filed: April 22, 2013
    Publication date: November 14, 2013
    Inventors: Nancy C. LAN, Yan Wang, Sui Xiong Cai
  • Publication number: 20130289003
    Abstract: A compound having the structure: useful for treating hypertension, Pulmonary Arterial Hypertension (PAH), congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy.
    Type: Application
    Filed: October 25, 2011
    Publication date: October 31, 2013
    Inventors: Amjad Ali, Michael Man-Chu Lo, Robert K. Baker, Zhiqiang Guo, Brent Whitehead, Timothy J. Henderson, Edward Metzger, Lin Yan, Shrenik K. Shah, James Dellureficio, Jun Wang
  • Publication number: 20130244945
    Abstract: An object of the present invention is to provide a medicament and method for treating lissencephaly patients. The present invention provides a lissencephaly therapeutic or preventive agent comprising a compound represented by the general formula (I): wherein R1 is lower alkyl substituted with lower alkoxy, lower alkyl substituted with a heterocyclic group, a heterocyclic group, or a group represented by the formula (IIa): wherein R4 is lower alkyl, R5 is lower alkylene, and m is an integer of 1 to 6; R2 is lower alkyl optionally substituted with phenyl; and R3 is lower alkyl optionally substituted with halogen, lower alkoxy, or phenyl; condensed polycyclic hydrocarbon; or hydrogen.
    Type: Application
    Filed: November 28, 2011
    Publication date: September 19, 2013
    Inventor: Shinji Hirotsune
  • Patent number: 8519159
    Abstract: 3,6-disubstituted pyrans, optionally with a further substituent at the 4-position, are monoamine reuptake inhibitors with activity profiles of anti-depressants.
    Type: Grant
    Filed: July 15, 2010
    Date of Patent: August 27, 2013
    Assignee: Wayne State University
    Inventor: Aloke K. Dutta
  • Publication number: 20130217762
    Abstract: The present invention provides novel selective androgen receptor modulators and their salts and pharmaceutical compositions thereof.
    Type: Application
    Filed: October 5, 2012
    Publication date: August 22, 2013
    Applicant: ELI LILLY AND COMPANY
    Inventor: Eli Lilly and Company
  • Patent number: 8513442
    Abstract: Methods of performing cycloadditions are described that include (a) combining a first reactant and a second reactant in a hydrogen bonding solvent to form a reaction mixture; and (b) reacting the first reactant and the second reactant to form a cycloadduct. Methods of performing asymmetric catalytic reactions are also described that include (a) combining a first reactant, a second reactant, and a catalytic amount of a chiral hydrogen-bond donor in a solvent to form a reaction mixture; and (b) reacting the first reactant and the second reactant to form an enantiomeric excess of a reaction product. Reaction mixtures corresponding to these methods are also described.
    Type: Grant
    Filed: June 11, 2007
    Date of Patent: August 20, 2013
    Assignee: The University of Chicago
    Inventors: Viresh H. Rawal, Yong Huang, Aditya K. Unni, Avinash N. Thadani
  • Publication number: 20130211098
    Abstract: The invention provides processes for preparing intermediates useful for preparing compounds of the formula: or a tautomer or salt thereof, where R1-R5, a, b, X and P2, are as defined in the specification.
    Type: Application
    Filed: February 14, 2013
    Publication date: August 15, 2013
    Inventor: Miroslav RAPTA
  • Publication number: 20130085283
    Abstract: Provided herein are geranylgeranylacetone derivatives and methods of using them.
    Type: Application
    Filed: March 1, 2012
    Publication date: April 4, 2013
    Inventors: Hiroaki Serizawa, Ankush B. Argade, Akash Datwani, Natalie Spencer
  • Publication number: 20130045951
    Abstract: The invention relates to nitroso derivatives including carboxylic acid and phosphoric acid esters of hydroxy nitroso compounds that donate nitroxyl (HNO) under physiological conditions. The compounds and compositions of the invention are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure, ischemia/reperfusion injury and cancer.
    Type: Application
    Filed: October 18, 2012
    Publication date: February 21, 2013
    Applicant: CARDIOXYL PHARMACEUTICALS, INC.
    Inventor: CARDIOXYL PHARMACEUTICALS, INC.
  • Publication number: 20120302759
    Abstract: The invention relates to a method for preparing a combretastatin derivative (I) or (II), said method including the following steps: triaryl(3,4,5-trimethoxybenzyl)phosphonium halide P3 (III), wherein Ar denotes an aryl group selected from among phenyl or thienyl, is reacted with P2 having formula (IV) or P?2 having formula (V) so as to respectively obtain the compound P4 or P?4, which have formulas (VI) and (VII), respectively; then, during a step for deprotection in the presence of an acid and/or a base, the compound having P4 or P?4 leads, after an optional purification step, to the compound having formula (I) or (II).
    Type: Application
    Filed: June 4, 2012
    Publication date: November 29, 2012
    Applicant: C/O SANOFI
    Inventors: Pascal BESSE, Eric DIDIER, Nicolas TREMAUDEUX
  • Patent number: 8309599
    Abstract: The present invention provides novel analogs of FR901464, as well as an improved methodology for preparing FR901464 and its analogs. These compounds display an anti-cancer activity and are candidates for therapies against a number of disease states associated with dysfunctional RNA splicing.
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: November 13, 2012
    Assignee: University of Pittsburgh-Of The Commonwealth System of Higher Education
    Inventors: Kazunori Koide, Brian J. Albert, Ananthapadmanabhan Sivaramakrishnan
  • Publication number: 20120282180
    Abstract: The present invention relates to the field of therapeutic and diagnostic agents and more specifically to compounds of formula (I) that are inhibitors of matrix-metalloproteinases (MMPs) and are useful in the treatment of diseases related thereto such as cardiovascular diseases, inflammatory diseases and malignant diseases. One embodiment of the invention is a compound of formula (I) labeled with a 18-fluorine atom having matrix metalloproteinase inhibitory activity suitable for diagnostic imaging. Also disclosed in the present invention is a pharmaceutical composition comprising the inhibitors of matrix-metalloproteinases (MMPs) of the invention or the corresponding labeled compounds useful as diagnostic imaging agents of the invention in a form suitable for mammalian administration.
    Type: Application
    Filed: June 8, 2011
    Publication date: November 8, 2012
    Inventors: Hartmuth C. Kolb, Guenter Haufe, Malte Behrends, Klaus Kopka, Stefan Wagner, Verena Hugenberg, Hans-Joerg Breyholz, Sven Hermann, Michael Schaefers
  • Publication number: 20120269771
    Abstract: The present invention discloses a new class of compounds that exhibit an inhibitory effect on influenza virus type A and B, which may or may not be resistant to other drugs, as well as on other types of viruses, such as flavivirus but also on protozoa and other micro-organisms, their preparation methods, pharmaceutical formulations containing them and their use as medicinal products for the treatment of various conditions caused by particular microorganisms, including viruses, bacteria and protozoa, which affect animal and human health.
    Type: Application
    Filed: November 25, 2010
    Publication date: October 25, 2012
    Inventors: Paolo Alberto Veronesi, Pablo E.A. Rodriguez, Anna Maria Veronesi, Emanuela Peschechera
  • Publication number: 20120232291
    Abstract: 4?-epidaunorubicin hydrochloride is provided in a crystalline form which is stable and readily soluble. A process of producing the crystalline form includes crystallizing 4?-epidaunorubicin hydrochloride in a solvent system including (a) solvent A selected from C1 and C2 halogenated solvents and mixtures thereof, (b) solvent B selected from C1-C5 straight and branched alcohols and mixtures thereof, and (c) solvent C selected from C1-C5 straight and branched alcohols and mixtures thereof, wherein solvent C is selected to provide lower solubility to 4?-epidaunorubicin hydrochloride than solvent B.
    Type: Application
    Filed: September 8, 2010
    Publication date: September 13, 2012
    Applicant: Heraeus Precious Metals GmbH & Co. KG
    Inventors: Tero Kunnari, Holger Bindernagel, Sascha Weiser, Andrew Lupton, Stefan Wallert
  • Publication number: 20120184606
    Abstract: Compounds having a structure of Formula I and compositions comprising these compounds are provided. Uses of such compounds and compositions are provided for treatment or prophylaxis of viral infection. In particular, compounds and compositions may be for use in the treatment or prophylaxis of viral influenza.
    Type: Application
    Filed: January 19, 2012
    Publication date: July 19, 2012
    Inventors: Stephen Withers, Andrew Graham Watts, Jin Hyo Kim, Tom Wennekes
  • Patent number: 8178658
    Abstract: The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed.
    Type: Grant
    Filed: February 11, 2009
    Date of Patent: May 15, 2012
    Assignee: Dow AgroSciences, LLC
    Inventors: Gary D. Crouse, Thomas C. Sparks, CaSandra L. McLeod, David A. Demeter, Kristy Bryan, Annette V. Brown, William H. Dent, III, Denise P. Cudworth, Jaime S. Nugent, Ricky Hunter, Jack G. Samaritoni
  • Patent number: 8173350
    Abstract: An oxime compound represented by the formula (I): wherein Y represents an unsubstituted or substituted n-valent C6-C14 aromatic hydrocarbon group, n represents an integer of 1 to 6, R1 represents a C1-C30 aliphatic hydrocarbon group etc., R2 represents a linear or branched chain C1-C20 aliphatic hydrocarbon group etc., W represents —CO—O— etc., Q1 and Q2 each independently represent a fluorine atom etc., Z represents a C1-C20 halogenated aliphatic hydrocarbon group etc, and the resist composition containing the same.
    Type: Grant
    Filed: July 21, 2009
    Date of Patent: May 8, 2012
    Assignee: Sumitomo Chemical Company, Limited
    Inventors: Tatsuro Masuyama, Kazuhiko Hashimoto, Takashi Hiraoka, Ichiki Takemoto
  • Publication number: 20120046331
    Abstract: This invention relates to new antifungal agents, compositions thereof, and methods for inhibiting the growth of fungi involved in infection and disease of keratinized tissue, such as onychomycosis. The invention also relates to new antifungal agents, compositions thereof, and methods for treating and/or preventing fungal infection and/or disease of keratinized tissue, such as onychomycosis. The invention further relates to a kit comprising said antifungal agent and use of said kit in treatment of fungal infection and/or disease of keratinized tissue, such as onychomycosis.
    Type: Application
    Filed: August 19, 2011
    Publication date: February 23, 2012
    Inventor: Jeffrey M. Besterman
  • Publication number: 20120046355
    Abstract: The present invention describes compounds of Formula I or a pharmaceutically acceptable salts or derivatives thereof. Compositions comprising compounds of Formula I are also described. The present invention further relates to a method of producing non-2-enonate compounds.
    Type: Application
    Filed: May 4, 2010
    Publication date: February 23, 2012
    Inventors: Ian C. Schoenhofen, Dennis M. Whitfield, Susan M. Logan
  • Publication number: 20120039815
    Abstract: The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds.
    Type: Application
    Filed: February 26, 2009
    Publication date: February 16, 2012
    Inventor: Hanno Priebe
  • Publication number: 20120022100
    Abstract: Disclosed are ?-amino-?-hydroxy-?-aryl-alkanoic acid amide compounds of formula (I) and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.
    Type: Application
    Filed: September 28, 2011
    Publication date: January 26, 2012
    Inventors: Juergen Klaus Maibaum, Daniel K. Baeschlin, Holger Sellner
  • Publication number: 20120016019
    Abstract: The present invention relates to a compound of the formula I: wherein R is C2H5 or C2H3, or a pharmaceutically acceptable salt or hydrate thereof, and a process for preparing said compound of the formula I. The invention also relates to the use of a composition comprising said compound of the formula I or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient, for treating or preventing cancers.
    Type: Application
    Filed: March 9, 2011
    Publication date: January 19, 2012
    Inventor: Gee-Hwoon LEE
  • Publication number: 20120014898
    Abstract: The present invention relates to the use of a composition comprising a compound of the formula I: wherein R is C2H5 or C2H3, or a pharmaceutically acceptable salt thereof, for preventing hair loss or stimulating hair growth.
    Type: Application
    Filed: July 29, 2010
    Publication date: January 19, 2012
    Inventor: Gee-Hwoon LEE
  • Publication number: 20120016017
    Abstract: The present invention relates to a compound of the formula I: wherein R is C2H5 or C2H3, or a pharmaceutically acceptable salt thereof, and a process for preparing said compound of the formula I. The invention also relates to the use of a composition comprising said compound of the formula I or a pharmaceutically acceptable salt thereof as an active ingredient, for treating or preventing cancers.
    Type: Application
    Filed: July 29, 2010
    Publication date: January 19, 2012
    Inventor: Gee-Hwoon LEE
  • Publication number: 20120016018
    Abstract: The present invention relates to the novel use of a composition comprising a compound of the formula I: wherein R is C2H5 or C2H3, or a pharmaceutically acceptable salt thereof, for inducing multiple nuclear divisions of cells; inducing tissues, blood vessels or organs to regenerate after the multiple nuclear divisions; or inducing stem cells to differentiate into immunocytes after the multiple nuclear divisions.
    Type: Application
    Filed: July 29, 2010
    Publication date: January 19, 2012
    Inventor: Gee-Hwoon LEE
  • Publication number: 20120004428
    Abstract: Novel 3,6-disubstituted pyrans, optionally with a further substituent at the 4-position, are monoamine reuptake inhibitors with activity profiles of anti-depressants.
    Type: Application
    Filed: September 13, 2011
    Publication date: January 5, 2012
    Applicant: WAYNE STATE UNIVERSITY
    Inventor: Aloke K. Dutta
  • Publication number: 20110172297
    Abstract: The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of Formula (I): as defined in the specification. The invention is also directed to compositions containing the compounds of Formula (I) as AMPA modulators.
    Type: Application
    Filed: September 18, 2009
    Publication date: July 14, 2011
    Inventors: Kimberly Gail Estep, Antone F.J. Fliri, Randall James Gallaschun, Christopher John O'Donnell, Nandini Chaturbhai Patel, Jacob Bradley Schwarz, Longfei Xie
  • Patent number: 7915433
    Abstract: Novel 3,6-disubstituted pyrans, optionally with a further substituent at the 4-position, are monoamine reuptake inhibitors with activity profiles of anti-depressants.
    Type: Grant
    Filed: April 15, 2005
    Date of Patent: March 29, 2011
    Assignee: Wayne State University
    Inventor: Aloke K. Dutta